Ligand Pharmaceuticals Incorporated
LGND · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $3,430,670 | $2,189,363 | $2,017,742 | $2,033,064 |
| - Cash | $664,522 | $67,669 | $47,989 | $72,307 |
| + Debt | $450,997 | $5,742 | $4,448 | $7,105 |
| Enterprise Value | $3,217,145 | $2,127,436 | $1,974,201 | $1,967,862 |
| Revenue | $115,461 | $47,627 | $45,333 | $42,812 |
| % Growth | 142.4% | 5.1% | 5.9% | – |
| Gross Profit | $90,641 | $44,720 | $40,484 | $39,975 |
| % Margin | 78.5% | 93.9% | 89.3% | 93.4% |
| EBITDA | $149,232 | $20,898 | -$40,543 | -$29,690 |
| % Margin | 129.2% | 43.9% | -89.4% | -69.3% |
| Net Income | $117,273 | $4,847 | -$42,451 | -$31,088 |
| % Margin | 101.6% | 10.2% | -93.6% | -72.6% |
| EPS Diluted | 5.68 | 0.24 | -2.21 | -1.64 |
| % Growth | 2,266.7% | 110.9% | -34.8% | – |
| Operating Cash Flow | $13,161 | $15,797 | -$25,516 | $28,471 |
| Capital Expenditures | -$15 | -$214 | -$214 | -$712 |
| Free Cash Flow | $13,146 | $15,583 | -$25,730 | $27,759 |